Second Quarter 2015 Highlights
Q2 2015 is 15th consecutive quarter of meeting or exceeding Company revenue guidance
Q2 2015 revenue of $45.7 million increased 79% over Q2 2014
Revenue is at the upper end of Company Q2 guidance
Q2 2015 Wound Care sales grew 73% over Q2 2014
Q2 2015 Surgical, Sports Medicine/Orthopedic revenue increased 104% over Q2 2014
Adjusted EBITDA* of $10.6 million represents a 265% improvement over Q2 2014
Q2 2015 net income of $5.4 million or $0.05 per diluted share vs Q2 2014 net loss of $390,000 or $0.00 per diluted share
Second Quarter and Six Months Ended June 30, 2015 Results
2013 about 70 million revenue, 2014 about 140 million, 2015 projected about 185 million with some projecting 250 million for 2016. Perhaps slower percent growth, but not as much in absolute dollar terms and the forward projections will be beaten.
This is an exciting foray into nerve repairs. Nerves are difficult to repair, especially if a nerve graft is required to bridge a defect. Nerve grafts are only moderately successful and nerve graft synthetic sheaths have been slightly less successful. If this product can bridge a nerve defect with successful nerve regeneration, the company would be worth billions on that alone. Imagine spinal cord repair. The product would likely be a ways off to hitting market.
From your July 29,2014 post, ".I'm clueless". You really are. Stem cells do become less predominant with advanced age and reduced vascularity. There was concern also using Infuseans lack of response due to advanced age. Infuse still stimulates good bone formation whether 80 or 20 years old. Likewise wound healing is enhanced in the aged group. Vascularity is a major concern. Hyperbaric oxygen has been used to prepare tissue beds for grafting bone. Epifix stimulates neovasvularization and stimulates surrounding stem cells for an extended period, about 6 weeks. The tissue bed is prepped to expose fresh, injured tissue. Since you are a Grafix badger, Grafix is a frozen, expensive to store and use product, it is more difficult to use and many of the 'live cell' do not survive the grafting. So, one is left with the ability to attract stem cells and advantage Epifix since it was properly prepared with Purion process to preserve growth factors released over 6 weeks. Docs, hospitals and clinics want Epifix because it works, it is easier to use and store and less costly to store and use.
You need to crawl back under the rock where you've been living.
It looks like HB responded to danielsonthegolfcourse who is likely Halloweencandy2013, cezasse9 etc. unless you are golfcourse. Point is Mimedx products work and Osiris products future is Cartiform. I don't think a frozen wound care product will do much. Ask Organogenesis.
Yes, this is a very important study. This proves the scientific basis behind everything associated with Purion DHACM. The growth factors and cytokines are preserved in the graft tissue and stimulate multiple stem cells including hematopoietic, bone and mesenchymal. These cells migrate to the area and produce more growth factors and cytokines (the cytokines reduce BAD chronic inflammation and produce GOOD HEALING inflammation). The factors stimulate new blood vessel ingrowth with new cell population and tissue growth in the once barren area.
On a side note, I have been using DHACM for bone grafting with great bone growth. I felt the necessary growth factors were in the DHACM to promote additional bone growth and this supports what I have seen clinically. Epifix/Amniofix works better than any product I have used for bone or soft tissue healing.
Mimedx will fetch up to 10X the following years revenue projections. So, if 300 million projected for 2016, could be 3 billion. I don't think it goes for
I haven't looked at BIO4, but Cartiform could be the game changer. Once your meniscus is gone, it is a compromise. Or how about a new ear? I will look closely at Osiris once Mdxg sold. I only have so much to invest.
I can tell you the live cells offer no advantage in avascular wounds. There are added costs with storage, limited shelf life, difficulty in usage and handling. You are wrong on many accounts. Grafix may play a minor role in wound care. Odiris other products seem interesting.